Erudio Healtherudio.com
Sponsor
GBG Forschungs trials: what clinicians said in public
No HCP commentary report on a trial sponsored by GBG Forschungs yet. Erudio has found public clinician commentary on 4 clinical trials sponsored by GBG Forschungs: GeparNuevo, GeparSixto, PENELOPE-B and SASCIA. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
Listed by lead sponsor as registered on ClinicalTrials.gov (GBG Forschungs GmbH). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| PENELOPE-B NCT01864746 · GBG Forschungs GmbH DeepView → | residual high-risk HR-positive HER2-negative early breast cancer | Phase 3 | Deep | View | |||
| GeparSixto NCT01426880 · GBG Forschungs GmbH DeepView → | triple-negative and HER2-positive early breast cancer | Phase 2/Phase 3 | Deep | View | |||
| GeparNuevo NCT02685059 · GBG Forschungs GmbH DeepView → | early triple-negative breast cancer | Phase 2 | Deep | View | |||
| SASCIA NCT04595565 · GBG Forschungs GmbH DeepView → | high relapse risk primary HER2-negative breast cancer | Phase 3 | Deep | View | |||